Skip to main content
SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. logo

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. — Investor Relations & Filings

Ticker · 688238 ISIN · CNE1000059N9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 486 across all filing types
Latest filing 2022-04-22 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688238

About SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD.

https://www.obio-tech.com/

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. is a specialized Contract Development and Manufacturing Organization (CDMO) focused on the gene and cell therapy (GCT) sector. The company provides end-to-end solutions encompassing vector construction, process development, analytical method development, and large-scale GMP manufacturing. Its service portfolio includes the production of viral vectors such as adeno-associated virus (AAV), lentivirus, adenovirus, and oncolytic viruses, as well as plasmid DNA and cell therapy products. Obio Technology supports clients from early-stage research through clinical trials to commercialization. The company operates advanced facilities designed to meet international regulatory standards, facilitating the development of innovative genetic medicines and advanced therapies for global biopharmaceutical partners.

Recent filings

Filing Released Lang Actions
和元生物技术（上海）股份有限公司章程（2022年4月)
Governance Information Classification · 95% confidence The document is a detailed company charter or articles of association, covering company organization, shareholder rights, board structure, share issuance, share transfer, shareholder meetings, and governance rules. It includes sections on share issuance, share repurchase, shareholder meetings, board and management roles, and legal compliance. There is no indication of financial statements, audit reports, earnings data, or meeting results. The content is focused on governance structure and shareholder meeting procedures, which aligns with Governance Information filings. The document is lengthy and substantive, not a brief announcement or notice. Therefore, the best fitting category is Governance Information (CGR).
2022-04-22 Chinese
关于使用暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement by a company regarding the use of temporarily idle raised funds for cash management. It details the board meeting resolutions, investment purposes, types of financial products for investment, investment limits and duration, risk control measures, and opinions from independent directors, supervisors, and the sponsoring institution. The document does not contain actual financial statements or comprehensive financial performance data but rather focuses on the company's decision and plan to manage idle funds from fundraising. It is a regulatory announcement about capital management activities related to fundraising proceeds, not a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is about 4962 characters, which is sufficient for a detailed announcement but not a full report like an annual or interim report. Hence, the classification is CAP with high confidence.
2022-04-22 Chinese
和元生物技术（上海）股份有限公司独立董事关于第二届董事会第二十四次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion statement from independent directors regarding various company matters such as profit distribution, audit firm reappointment, related party transactions, cash management, remuneration plans, and board member nomination. It references compliance with company law, company articles, and regulatory requirements. The document does not contain financial statements or detailed financial data but rather expresses independent directors' opinions on proposals to be submitted to the shareholders' meeting. It is a governance-related document focused on board and management matters, including director nomination and remuneration. Therefore, it fits best under Board/Management Information (MANG). The document length is short (2110 characters), and it is not an announcement of a report but an opinion statement related to board decisions.
2022-04-22 Chinese
和元生物技术（上海）股份有限公司独立董事关于第二届董事会第二十四次会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion statement from independent directors regarding various company matters such as profit distribution, audit firm reappointment, related party transactions, cash management, remuneration plans, and board member nomination. It references compliance with company law, company articles, and regulatory requirements. The document does not contain financial statements or detailed financial data but provides opinions on proposals to be submitted to the shareholders' meeting. The length is about 2110 characters, which is relatively short and consistent with an announcement or opinion letter rather than a full report. This type of document is typically part of governance or board-related disclosures but is not a full management report or annual report. It is best classified under Regulatory Filings (RNS) as it is a regulatory announcement of independent directors' opinions on board meeting matters, not the meeting materials themselves or the final voting results.
2022-04-22 Chinese
和元生物技术（上海）股份有限公司独立董事关于第二届董事会第二十四次会议相关事项的独立意见
Governance Information Classification · 95% confidence The document is an independent opinion statement from independent directors regarding various company matters such as profit distribution, audit firm reappointment, related party transactions, cash management, remuneration plans, and board member nomination. It references compliance with company law, company articles, and regulatory requirements. The document does not contain financial statements or detailed financial data but provides opinions on proposals to be submitted to the shareholders' meeting. The length is about 2110 characters, which is relatively short and consistent with an announcement or opinion letter rather than a full report. The content aligns with a governance-related document, specifically opinions on board meeting matters and proposals for shareholder approval. Therefore, the document fits best under the category of Governance Information (CGR).
2022-04-22 Chinese
关于公司董事辞职暨补选董事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company director and the nomination of a new director. It includes details about the outgoing director's resignation, the nomination process for the new director, and the independent directors' opinion on the nomination. There is no financial data, earnings information, or report publication mentioned. The content clearly relates to changes in the company's board of directors, which fits the category of Board/Management Information (MANG). The document length is short and focused solely on management changes, confirming it is not a full report or announcement of a report publication.
2022-04-22 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.